InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,803.20
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
57,849.87
(
-0.08%
)
Post# of 252586
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: WorstLuck post# 208547

Monday, 01/30/2017 10:35:59 AM

Monday, January 30, 2017 10:35:59 AM

Post# of 252586

The bane of modest financial resources combined with modest efficacy.

You're quite right. OCRX will not go anywhere with the IV formulation of OCR-002 if they can't do better than HR=0.80 vs placebo. The company's task now is to get the dose up to the point where the efficacy is clinically meaningful. The AE profile suggests that this is an achievable goal.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up